References in periodicals archive ?
According to the data from the British Society for Rheumatology Biologics Register (BSRBR), patients with higher levels of inflammatory markers at baseline responded better to anti-TNF therapy [level of evidence IIb].
Louise Mercer, a clinical research fellow at the Arthritis Research UK Epidemiology Unit, University of Manchester, England, where the BRSBR is coordinated (Rheumatology 2011;50:iii37-8, abstract OP18) noted that they set a baseline for analyzing the cancer risk of biologic therapy, compared with conventional RA therapy within the BSRBR patient population.
Symmons, also of the Arthritis Research UK Epidemiology Unit in Manchester and a principal investigator for the BSRBR, explained that this adds to the evidence that "the cancer risk in our general rheumatoid population is increased for some cancers."
The investigators identified 177 patients (1.6%) with a prior malignancy among the 10,723 people enrolled in the British Society for Rheumatology Biologics Registry (BSRBR) and 118 cases (3.6%) of past cancer among 3,236 people whose RA was treated with traditional disease-modifying antirheumatic drugs (DMARDs) at 32 U.K.
The BSRBR is funded indirectly by Schering-Plough, Wyeth Laboratories, Abbott Laboratories, Roche, Centocor, and Amgen/Genentech.
BIRMINGHAM, ENGLAND -- No important differences in rates of serious infections have been reported among patients treated with etanercept, infliximab, or adalimumab, according to a report from the British Society for Rheumatology Biologics Register (BSRBR).
Acronyms browser ?
Full browser ?